Home | Community | Get Involved | Donate | | Site Index | Search Go Button
The mark, American Cancer Society, is a registered trademark of the American Cancer Society, Inc., and may not be copied, reproduced, transmitted, displayed, performed, distributed, sublicensed, altered, stored for subsequent use or otherwise used in whole or in part in any manner without ACS's prior written consent.
 
My Planner Register | Sign In Sign In


Press Room
 
    Press Releases
    Media Relations Contacts
    Online Press Kit
    Rumors, Myths, and Truths
Glossary
About the American Cancer Society
   
FDA Advisory Committee Recommmends FDA Approval of Herceptin for Treatment of Breast Cancer
1998/09/03 -The Food and Drug Administration's (FDA) Oncology Drugs Advisory Committee has recommended (September 3, 1998) that the FDA approve the drug Herceptin, a biologically engineered antibody that has shown promise in treating women with advanced breast cancer. The FDA is not bound by the committee's recommendations, but usually follows them. A final decision is expected in November.

More information on the current availability of Herceptin can be obtained by calling the manufacturer, Genentech, at 888-777-4464.





Joann Schellenbach
National Director Media Relations
American Cancer Society
212-382-2169
jschelle@cancer.org







Printer-Friendly Page
Email this Page
Related Tools & Topics
ACS News Center  
Talk to Your Legislators  
Research Program and Funding  
Learn About Cancer  
Statistics  
Not registered yet?
  Register now or see reasons to register.  
Help |  About ACS |  Employment & Volunteer Opportunities |  Legal & Privacy Information |  Press Room
Copyright 2009 © American Cancer Society, Inc.
All content and works posted on this website are owned and
copyrighted by the American Cancer Society, Inc. All rights reserved.